Prevention of Maternal-fetal Cytomegalovirus Transmission After Primary Maternal Infection, GW ≤ 14 (PreCyssion)
Status:
Recruiting
Trial end date:
2024-08-31
Target enrollment:
Participant gender:
Summary
A phase 3, open-label, single-arm, prospective, multi-center trial of Cytotect CP Biotest
(BT097) for prevention of maternal-fetal CMV transmission after primary maternal CMV
infection. The main purpose of the trial is to demonstrate efficacy and safety of Cytotect CP
Biotest in preventing maternal-fetal transmission of cytomegalovirus (CMV).